Author: Ian Mason

Italy’s Dompé has unveiled ambitious expansion plans, with chief executive Eugenio Aringhieri telling PharmaTimes that its rhNGF (recombinant human nerve growth factor) will be the springboard that will transform the company.

InterMune, which is in the process of being acquired by Roche for $8.3 billion, says that data over 72 weeks provides further evidence of a durable pirfenidone treatment benefit on multiple measures of idiopathic pulmonary fibrosis including reducing the risk of mortality.

AstraZeneca’s Phase III pipeline is growing ahead of plan, chief executive  Pascal Soriot told a recent media briefing, and cancer drugs make up a major chunk of the pipeline.

Menarini has launched ‘Firing Too Quickly’ – a UK campaign designed to raise public and healthcare provider awareness of premature ejaculation and its treatment.

There was good and bad news for analgesia-focused pharmaceutical companies at the European Pain Federation (EFIC) Congress, which was held in Florence.